Session » Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes II: Morbidity & Mortality (1716–1721)
- 3:00PM-3:15PM
-
Abstract Number: 1716
The frequency and impact of cardiovascular disease in systemic lupus erythematosus: a Nationwide, matched case-control study.
- 3:15PM-3:30PM
-
Abstract Number: 1717
The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Mortality In Systemic Lupus Erythematosus (SLE) Patients: Data From The Almenara Lupus Cohort
- 3:30PM-3:45PM
-
Abstract Number: 1718
Mortality and Hematological Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors: Impact of Pre-existing Systemic Lupus Erythematosus
- 3:45PM-4:00PM
-
Abstract Number: 1719
Impact of SGLT2 Inhibitors on Cardiovascular Events, Mortality, and Lupus Nephritis in Patients with Systemic Lupus Erythematosus and Diabetes: Retrospective Cohort Study
- 4:00PM-4:15PM
-
Abstract Number: 1720
Comparison of Mortality Trends in Adults with Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A 21-Year Analysis Using CDC WONDER DATABASE.
- 4:15PM-4:30PM
-
Abstract Number: 1721
Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study